Shanghai Junshi Bioscience Co., Ltd.

This early-stage study tests a new drug, JS207, in about 98 adults with advanced solid tumors that have not responded to standard treatments or have no standard therapy. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Research…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before and after surgery helps people with a certain type of advanced esophageal cancer. About 663 participants will receive either toripalimab or a placebo along with chemo, then surgery,…

This study tests whether adding toripalimab (an immunotherapy) to lenvatinib (a targeted therapy) helps people with advanced liver cancer live longer. About 530 adults with advanced hepatocellular carcinoma (HCC) that cannot be treated with surgery will receive either the combina…

This early-stage study tests a new drug called JS203 in about 104 adults with B-cell non-Hodgkin's lymphoma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. Participants must b…